PE20170299A1 - Proteinas agonistas de los receptores de trail de cadena simple - Google Patents
Proteinas agonistas de los receptores de trail de cadena simpleInfo
- Publication number
- PE20170299A1 PE20170299A1 PE2016002016A PE2016002016A PE20170299A1 PE 20170299 A1 PE20170299 A1 PE 20170299A1 PE 2016002016 A PE2016002016 A PE 2016002016A PE 2016002016 A PE2016002016 A PE 2016002016A PE 20170299 A1 PE20170299 A1 PE 20170299A1
- Authority
- PE
- Peru
- Prior art keywords
- agonists
- proteins
- single chain
- trail receptors
- chain trail
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 title 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 108700012411 TNFSF10 Proteins 0.000 abstract 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170299A1 true PE20170299A1 (es) | 2017-05-06 |
Family
ID=53055121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002016A PE20170299A1 (es) | 2014-04-23 | 2015-04-23 | Proteinas agonistas de los receptores de trail de cadena simple |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3292143B1 (en) * | 2015-05-04 | 2019-08-21 | Apogenix AG | Single-chain cd40-receptor agonist proteins |
| AU2016342420B2 (en) * | 2015-10-23 | 2020-10-01 | Apogenix Ag | Single-chain LIGHT receptor agonist proteins |
| CN108430492B (zh) | 2015-10-23 | 2022-05-03 | 阿珀吉科吉尼科斯股份公司 | 单链cd27受体激动剂蛋白 |
| JP6959229B2 (ja) * | 2015-10-23 | 2021-11-02 | アポジェニックス アーゲー | 一本鎖ｇｉｔｒ受容体アゴニストタンパク質 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CA3054286A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
| JP2019518713A (ja) * | 2016-03-16 | 2019-07-04 | メリマック ファーマシューティカルズ インコーポレーティッド | 癌療法のための改変ｔｒａｉｌ |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3027380A1 (en) * | 2016-06-13 | 2017-12-21 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| US11578315B2 (en) | 2017-08-11 | 2023-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig L-asparaginase variants and methods of use |
| WO2019178433A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| EP4149964A2 (en) | 2020-05-15 | 2023-03-22 | Apogenix AG | Multi-specific immune modulators |
| CA3217894A1 (en) | 2021-05-28 | 2022-12-01 | Gernot Stuhler | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| PT1355942E (pt) | 2000-12-07 | 2008-11-21 | Lilly Co Eli | Proteínas de fusão de glp-1 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538088B2 (en) | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| CA2597789A1 (en) | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| WO2009007120A2 (en) | 2007-07-10 | 2009-01-15 | Apogenix Gmbh | Tnf superfamily collectin fusion proteins |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2806029B1 (en) * | 2008-07-21 | 2016-05-25 | Apogenix AG | TNFSF single chain molecules |
| JP2012502994A (ja) * | 2008-09-22 | 2012-02-02 | アムジエン・インコーポレーテツド | 治療方法 |
| JP2012504969A (ja) * | 2008-10-10 | 2012-03-01 | アナフォア インコーポレイテッド | Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド |
| US8664366B2 (en) | 2009-01-09 | 2014-03-04 | Apogenix Gmbh | Fusion proteins forming trimers |
| EP2389192A4 (en) * | 2009-01-23 | 2013-01-16 | Biogen Idec Inc | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE |
| AU2010334974A1 (en) | 2009-12-22 | 2012-07-12 | Novartis Ag | Tetravalent CD47-antibody constant region fusion protein for use in therapy |
| CN102906112B (zh) * | 2010-04-13 | 2016-12-07 | 米迪缪尼有限公司 | Trail r2-特异性多聚体支架 |
| WO2013092983A2 (en) * | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN104662039B (zh) | 2012-07-18 | 2019-10-08 | 阿珀吉尼科斯股份公司 | 缩短的CD95-Fc变体 |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170299A1 (es) | Proteinas agonistas de los receptores de trail de cadena simple | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| ECSP18082207A (es) | Neoantígenos y métodos de su uso | |
| CO2017008047A2 (es) | Polipéptidos que se unen a proteínas de la superfamilia del receptor del factor de necrosis tumoral | |
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| CY1122803T1 (el) | Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων | |
| CL2017002244A1 (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015). | |
| HUE058044T2 (hu) | Fenilpirrolidinon-formil peptid 2 receptor agonisták | |
| PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
| PL3322717T3 (pl) | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem nabłonkowego raka jajnika i innych rodzajów raka | |
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| EP3765501C0 (en) | COMBINATION THERAPY WITH TARGETED 4-1 BB (CD137) AGONISTS | |
| EA201791253A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| BR112018007296A2 (pt) | conjugados de anticorpo compreendendo agonista de receptor tipo toll | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| EA201591661A1 (ru) | Пептиды и композиции для лечения повреждений суставов | |
| CY1123738T1 (el) | Προσδετες που ενισχυουν τη βιοδραστικοτητα των γοναδοτροπινων | |
| MX2015015043A (es) | Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado. | |
| PL3319985T3 (pl) | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka przełyku i innych rodzajów raka | |
| PE20161152A1 (es) | Anticuerpos y metodos de uso | |
| MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins |